Regeneron Pharmaceuticals Inc (REGN)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $98.84B
Last updated: Nov 17, 2026 at 11:06 AM ET
Regeneron Pharmaceuticals Inc (REGN) Competitors
The companies most similar to Regeneron Pharmaceuticals are BeOne Medicines AG (ONC), Moderna (MRNA) and argenx NV ADR (ARGX). Regeneron Pharmaceuticals trades at 18.4x earnings, against a median of 33.5x for the 5 of these companies with a P/E. By market cap, Regeneron Pharmaceuticals ranks 2nd of the 13 companies on this page; Vertex Pharmaceuticals (VRTX) is the largest at $136.56B.
Peer Comparison
REGN's ROIC of 13.7% is above the peer median of -28.5%, and its revenue growth of 36.3% is above the median of 22.6%. It yields 0.39%, while the median peer pays no dividend.
| Company | Market cap | P/E | P/S | Net margin | ROIC | Rev growth | Div yield |
|---|---|---|---|---|---|---|---|
| Regeneron Pharmaceuticals (REGN) | $98.84B | 18.4x | 5.7x | 28.5% | 13.7% | 36.3% | 0.39% |
| BeOne Medicines AG (ONC) | $47.58B | 50.0x | 18.7x | 13.9% | 7.5% | 33.8% | 0.00% |
| Moderna Inc (MRNA) | $90.38B | N/A | 34.2x | -110.5% | -28.9% | 29.2% | 0.00% |
| argenx NV ADR (ARGX) | $60.37B | 33.5x | 6.1x | 31.7% | N/A | 52.1% | 0.00% |
| Vertex Pharmaceuticals Inc (VRTX) | $136.56B | 30.0x | 10.5x | 30.7% | 14.2% | 11.8% | 0.00% |
| Royalty Pharma Plc (RPRX) | $39.85B | 12.9x | 11.7x | 25.7% | 7.6% | 13.3% | 1.37% |
| Genmab AS (GMAB) | $31.67B | 35.8x | 19.2x | 17.0% | 4.8% | 16.1% | 0.00% |
| Revolution Medicines Inc (RVMD) | $37.27B | N/A | 181.6x | 0.0% | -52.1% | -95.2% | 0.00% |
| Roivant Sciences Ltd (ROIV) | $28.64B | N/A | 679.3x | 0.0% | N/A | 2136.0% | 0.00% |
| Regenxbio Inc (RGNX) | $505.18M | N/A | 3.1x | -113.9% | N/A | -69.2% | 0.00% |
| BridgeBio Pharma Inc (BBIO) | $15.25B | N/A | 16.0x | -59.8% | -33.0% | 192.6% | 0.00% |
| Neurogene Inc (NGNE) | $495.37M | N/A | N/A | 0.0% | -28.5% | 0.0% | 0.00% |
| Insmed Inc (INSM) | $26.58B | N/A | 17.7x | -39.9% | -44.2% | 268.4% | 0.00% |
| Peer median | $34.47B | 33.5x | 17.7x | 0.0% | -28.5% | 22.6% | 0.00% |
Similar Companies
These are the 12 companies most similar to Regeneron Pharmaceuticals, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.
| Company | About | Peers |
|---|---|---|
| BeOne Medicines AG (ONC) | BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe... | ONC competitors |
| Moderna Inc (MRNA) | Moderna, Inc., a biotechnology company, develops messenger RNA-based vaccines and therapies for the treatment of infectious diseases, immuno-oncology... | MRNA competitors |
| argenx NV ADR (ARGX) | argenx SE, a clinical-phase biotechnology company, focuses on the development of antibody-based therapies for the treatment of autoimmune diseases... | ARGX competitors |
| Vertex Pharmaceuticals Inc (VRTX) | Vertex Pharmaceuticals, Inc. is an American biopharmaceutical company based in Boston, Massachusetts. | VRTX competitors |
| Royalty Pharma Plc (RPRX) | Royalty Pharma plc is a buyer of biopharmaceutical royalties and funder of innovations in the biopharmaceutical industry in the United States. | RPRX competitors |
| Genmab AS (GMAB) | Genmab A / S develops antibody therapies for the treatment of cancer and other diseases mainly in Denmark. The company is headquartered in Copenhagen, Denmark. | GMAB competitors |
| Revolution Medicines Inc (RVMD) | Revolution Medicines, Inc., a precision clinical-stage oncology company, is focused on developing therapies to inhibit borderline targets in RAS-addicted... | RVMD competitors |
| Roivant Sciences Ltd (ROIV) | Roivant Sciences Ltd (ROIV) is a transformative biopharmaceutical company focused on advancing drug development and commercialization through a distinctive... | ROIV competitors |
| Regenxbio Inc (RGNX) | REGENXBIO Inc., a clinical-stage biotechnology company, offers candidate gene therapy products to deliver genes to cells to address genetic defects or to enable... | RGNX competitors |
| BridgeBio Pharma Inc (BBIO) | BridgeBio Pharma, Inc. is dedicated to the discovery, development and supply of various drugs for genetic diseases. | BBIO competitors |
| Neurogene Inc (NGNE) | Neurogene Inc. is an innovative biotechnology company at the forefront of developing advanced gene therapies for rare neurological disorders... | NGNE competitors |
| Insmed Inc (INSM) | Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. | INSM competitors |
Frequently Asked Questions About REGN
Who are Regeneron Pharmaceuticals' main competitors?
The companies most similar to Regeneron Pharmaceuticals include BeOne Medicines AG (ONC), Moderna (MRNA), argenx NV ADR (ARGX), Vertex Pharmaceuticals (VRTX) and Royalty Pharma Plc (RPRX), listed from the closest match.
Who is Regeneron Pharmaceuticals' biggest competitor?
Vertex Pharmaceuticals (VRTX) is the largest of the similar companies at $136.56B; BeOne Medicines AG (ONC) is the closest match by business profile, size, sector and industry.
How does REGN stock compare with its competitors?
REGN's P/E is 18.4x against a peer median of 33.5x; its P/S is 5.7x against a peer median of 17.7x; its net margin is 28.5% against a peer median of 0.0%.
Which of Regeneron Pharmaceuticals' competitors pays a higher dividend?
Regeneron Pharmaceuticals has a forward dividend yield of 0.39%. Royalty Pharma Plc (RPRX) has a higher forward dividend yield; Royalty Pharma Plc (RPRX) has the highest at 1.37%.
Is Regeneron Pharmaceuticals bigger than its competitors?
No. Regeneron Pharmaceuticals is 2nd by market cap among the 13 companies on this page; the largest is Vertex Pharmaceuticals (VRTX) at $136.56B.
REGN pages: Overview, Dividends, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts